Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: NCCTG-N0189
NCT Study ID (ClinicalTrials.gov): NCT00053027
Disease or Cancer Type: Lymphoma
Alliance Study Chair: David J. Inwards, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy such as cladribine work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with cladribine may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with cladribine works in treating patients with newly-diagnosed mantle cell lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information